TARGET RESEARCH ARTICLES
-
Can CoRegen's Treg Platform Dismantle Solid Tumors' Immune Shield?
Backed by $93 million, CoRegen is bringing a novel Treg-engineering strategy into the clinic to test whether CRG-150 can dismantle solid tumors’ immune defenses.
-
Discovery & Development US 2026 - Key Notes From San Diego
Key takeaways from D&D US 2026 on Pfizer’s complex oncology targets, AI-enabled discovery, and the shift toward human-based NAMs.
-
Inside Discovery On Target 2026: New Modalities, AI, And A Higher Funding Bar
Discovery on Target 2026 showed how new modalities and AI are expanding drug discovery as investors demand stronger data and clearer paths to value.
-
Targeting p27 To 'Let Biology Do The Work' With Stacy Blain, CEO, Concarlo Therapeutics
Stacy Blain, PhD, turned 30 years of p27 research into Concarlo’s LOCKTAC, a molecular glue designed to restore natural CDK2/4/6 inhibition in cancer.
-
Viewing Treatment Resistance As A Target
Viewing treatment resistance as a target instead of an undesirable side effect could allow effective treatments to work for longer.
-
Target Transcription Factor States, Not Pockets
Transcription factors expose broad protein–DNA and protein–protein interfaces, contain intrinsically disordered regions, and exchange partners as cellular context changes.
TARGET RESEARCH ARTICLES. APP NOTES, CASE STUDIES. & WHITE PAPERS
-
Ionizable lipid selection ratios shape how well lipid nanoparticles deliver nucleic acids, and empirical testing shows that similar physical properties can still produce very different performance.
-
Discover how EPR complements structural maps by resolving flexible regions, detecting hidden conformational states, identifying differences between grid-based and solution conditions, and revealing the dynamic changes that connect molecular structure with biological function.
-
Explore a scalable RNA-seq approach that delivers reproducible, high-quality transcriptomic data from checkpoint-edited T-cells, uncovering gene expression changes linked to PD-1 and TIGIT deletion.
-
Discover how automated EPR pulsed dipolar spectroscopy measures protein dynamics, complements Cryo-EM and AlphaFold, and delivers crucial structural insights for drug discovery.
-
Targeted LNPs that bypass the liver and home to the spleen could reshape in vivo CAR T cell manufacturing. See the data behind the approach.
-
Resolving dynamic states in membrane proteins is vital for drug discovery. EPR spectroscopy tracks conformational shifts in native environments, bypassing standard structural limits.
TARGET RESEARCH SOLUTIONS
-
Capturing dynamic conformational states is key to target druggability. Advanced EPR spectroscopy delivers nanometer-resolution measurements for complex structural biology.
-
Macrocycles expand drug discovery into previously inaccessible targets. With validated success and flexible approaches, they provide a powerful path for tackling the most challenging biology.
-
CHO cells have been the workhorse for protein and antibody manufacturing. The major advantages of CHO include robust growth, hardiness in suspension culture, stellar protein production and secretion, and a long track record.
-
HEK293 cells have been the most popular mammalian transient production platform. The primary advantage of HEK293 cells is transfection efficiency.
-
The demand for high-throughput antibodies has exponentially increased over the last couple of years and has rapidly accelerated the antibody screening process.
-
E. coli is often the system of choice for biomanufacturing because of its amenability to genetic manipulation, low production cost, and rapid timelines for bioexpression.
-
Curia provides a wide range of biochemical and cell-based bioassay workflows to support Discovery, Research & Development as well as cGxP therapeutic testing campaigns
-
We deliver custom assay development, screening, potency, and selectivity testing services for the pharmaceutical, biopharmaceutical, and agrochemical industries.
-
Evaluating small and large molecule therapeutics within cellular environments is essential to understanding their efficacy, potency, and safety within a complex biological system.
-
Curia’s expert scientists use advanced technology to produce and analyze high-quality recombinant proteins.
-
Curia’s discovery biology team accelerates your program toward the clinic and commercialization with our best-in-class, customizable solutions.
-
At Curia, our team of expert protein chemists and structural biologists brings the advanced experience and technology needed to support all your structural biology services needs.
-
High‑throughput scNMT‑seq offers a powerful way to map methylation and transcriptional activity. Learn about strategies that cut variability and support dependable multi‑omics datasets.
-
Generate human-relevant data with an Organ-Chip system that combines automation, imaging, and cost efficiency for faster, more confident insights for drug development and complex biological studies.